Overview

This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

Eligibility

Key Inclusion Criteria:

• 18 years of age or older
• Diagnosed with one of the following at least 3 months prior to screening: schizophrenia or schizoaffective disorder, bipolar disorder, or major depressive disorder
• Diagnosed with at least mild neuroleptic-induced TD for at least 3 months prior to screening

Key Exclusion Criteria:

• Have comorbid Parkinsonism or abnormal involuntary movement(s) that is more prominent than TD
• Diagnosis of moderate or severe substance use disorder in the last 6 months
• History of long QT syndrome, cardiac arrythmia, or severe hepatic impairment